35 min
PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape PeerView Gastroenterology CME/CNE/CPE Video Podcast
-
- Science
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.
Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
PD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Co-Chair/Planner
Jonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.
Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
PD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Co-Chair/Planner
Jonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
35 min